1. Home
  2. Clinical Topics
  3. FDA approves Surfaxin to prevent respiratory distress syndrome in premature infants.
Clinical TopicsDrugs and DevicesPediatricsWeb Exclusives

FDA approves Surfaxin to prevent respiratory distress syndrome in premature infants.

Share

On March 6, the U.S. Food and Drug Administration (FDA) announced the approval of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome in premature infants. Read more.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts